NCT03225196 is a clinical trial in Subclinical Atherosclerotic Cardiovascular Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT03225196?

NCT03225196 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Is NCT03225196 still recruiting?

NCT03225196 is currently completed. Last updated 15 December 2023.

Last reviewed 2023-12-15 · How we verify

NCT03225196

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extracellular RNAs in Relation to Cardiometabolic Risk

Completed Last updated 15 December 2023

What this trial tests

trial in Subclinical Atherosclerotic Cardiovascular Disease in 4,495 participants. Completed in 11 June 2020.

Timeline

17 July 2017

Primary endpoint
11 June 2020

11 June 2020

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4,495
Start date	17 July 2017
Primary completion	11 June 2020
Estimated completion	11 June 2020
Sites	1 location across United States

Conditions studied

Subclinical Atherosclerotic Cardiovascular Disease — all drugs for Subclinical Atherosclerotic Cardiovascular Disease →
Blood Pressure — all drugs for Blood Pressure →
Obesity — all drugs for Obesity →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

Adults 21 to 90, any sex, with Subclinical Atherosclerotic Cardiovascular Disease or Blood Pressure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Extracellular RNAs (exRNAs) send genetic data from cell to cell. This is how they affect the way cells communicate with each other. There are many types of exRNA, and they each serve different roles. But they have also been linked to some diseases. Researchers want to measure exRNAs to see how they relate to certain traits over time. They will use blood samples that were taken as part of the Framingham Heart Study (FHS). Objectives: To identify cross-sectional associations of exRNAs with age, sex, and cardiometabolic risk factors. Eligibility: People ages 30-70 who had blood taken as part of the FHS Third Generation cohort. Design: Researchers will study samples that have already been collected in the FHS. There will be no active participant contact for this project, only use of data that are collected as part of planned follow up from other studies. As part of the FHS, participants gave blood samples. They gave permission for the blood to be used for research. The exRNAs from the blood samples will be studied to see how they relate to certain traits. These include age, sex, and body mass index. The exRNAs will also be studied for their usefulness as biomarkers of risk for subclinical atherosclerotic cardiovascular disease. No study participants will be contacted for this study....

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis.
Zimbru RI, Zimbru EL, Bojin FM, Haidar L, et al · · 2025 · cited 2× · PMID 40332077 · DOI 10.3390/ijms26083570

Verify or expand the search:

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03225196 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: 15 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03225196.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing